ALLO (STOCKS)
Allogene Therapeutics, Inc. Common Stock
$1.660000
-0.030000 (-1.78%)
Prev close: $1.690000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- David D. Chang
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $373.05M
- Employees
- 361
- P/E (TTM)
- -1.72
- P/B (TTM)
- 1.20
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
11
Buy
2
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.19 | $-0.23 | +0.0377 | +16.56% |
|
Jun 2025 (Q2)
|
$-0.23 | $-0.28 | +0.0490 | +17.56% |
|
Mar 2025 (Q1)
|
$-0.28 | $-0.30 | +0.0155 | +5.25% |
|
Dec 2024 (Q4)
|
$-0.28 | $-0.34 | +0.0600 | +17.65% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $15.83M |
| Operating Expenses | $227.40M |
| Research and Development | $166.49M |
| Other Operating Expenses | $60.91M |
| Operating Income/Loss | -$227.40M |
| Income/Loss From Continuing Operations After Tax | -$212.02M |
| Income/Loss From Continuing Operations Before Tax | -$211.57M |
| Income/Loss From Equity Method Investments | $0.00 |
| Net Income/Loss | -$212.02M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$212.02M |
| Net Income/Loss Available To Common Stockholders, Basic | -$212.02M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.98 |
| Diluted Earnings Per Share | -$0.98 |
| Basic Average Shares | 224,091,944 |
| Diluted Average Shares | 224,091,944 |
| Assets | $439.77M |
| Current Assets | $260.72M |
| Cash | $277.10M |
| Noncurrent Assets | $179.05M |
| Fixed Assets | $75.90M |
| Other Non-current Assets | $103.16M |
| Liabilities | $124.44M |
| Current Liabilities | $31.83M |
| Accounts Payable | $3.70M |
| Other Current Liabilities | $28.13M |
| Noncurrent Liabilities | $92.61M |
| Equity | $315.33M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $315.33M |
| Liabilities And Equity | $439.77M |
| Net Cash Flow From Operating Activities | -$158.35M |
| Net Cash Flow From Operating Activities, Continuing | -$158.35M |
| Net Cash Flow From Investing Activities | $116.88M |
| Net Cash Flow From Investing Activities, Continuing | $116.88M |
| Net Cash Flow From Financing Activities | $28.04M |
| Net Cash Flow From Financing Activities, Continuing | $28.04M |
| Net Cash Flow | -$13.42M |
| Net Cash Flow, Continuing | -$13.42M |
| Comprehensive Income/Loss | -$211.94M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$211.94M |
| Other Comprehensive Income/Loss | $78.00K |